**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 18193**

**Manuscript Type: TOPIC HIGHLIGHT**

**2015 Advances in *Helicobacter pylori***

***Helicobacter pylori* and colorectal neoplasia: Is there a causal link?**

Papastergiou V *et al. Helicobacter pylori* infection colorectal neoplasm

Vasilios Papastergiou, Stylianos Karatapanis, Sotirios D Georgopoulos

**Vasilios Papastergiou, Stylianos Karatapanis,** Department of Internal Medicine, General Hospital of Rhodes, 85100 Rhodes, Greece

**Sotirios D Georgopoulos,** Department of Gastroenterology, Athens Medical, P. Faliron Hospital, 17562 Athens, Greece

**Author contributions:** Papastergiou V contributed to conception and design, drafting the article; Georgopoulos SD contributed to drafting the article, revising the article critically for important intellectual content; Karatapanis S contributed to final approval of the version to be published.

**Conflict-of-interest statement:** The authors have nothing to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Sotirios D Georgopoulos, MD, FEBGH, AGAF, Director,** Division of Internal Medicine, Department of Gastroenterology, Athens Medical, Paleon Faliron General Hospital, Areos 36, Paleon Faliron, 17562 Athens, Greece. [georgpap@ath.forthnet.gr](mailto:georgpap@ath.forthnet.gr)

**Telephone:** +30-2109892100

**Received:** April 10, 2015

**Peer-review started:** April 11, 2015

**First decision:** May 18, 2015

**Revised:** July 1, 2015

**Accepted:** September 30, 2015

**Article in press:**

**Published online:**

**Abstract**

Ever since *Helicobacter pylori (H. pylori)* was been recognized as an infectious cause of gastric cancer, there has been increasing interest in examining its potential role in colorectal carcinogenesis. Data from case-control and cross-sectional studies, mostly relying on hospital-based samples, and several meta-analyses have shown a positive statistical relationship between *H. pylori* infection and colorectal neoplasia. However, the possibility exists that the results have been influenced by bias, including improper selection of patients and disparities with respect to potential confounders. While the evidence falls short of a definitive causal link, it appears that infection with *H. pylori*/*H. pylori*-related gastritis is associated with an increased, although modest, risk of colorectal adenoma and cancer. The pathogenic mechanisms responsible for this association remain uncertain. *H. pylori* has been detected in colorectal malignant tissues; however, the possibility that *H. pylori* is a direct activator of colonic carcinogenesis remains purely hypothetical. On the other hand, experimental data have indicated a series of potential oncogenic interactions between these bacteria and colorectal mucosa, including induction and perpetuation of inflammatory responses, alteration of gut microflora and release of toxins and/or hormonal mediators, such as gastrin, which may contribute to tumor formation.

**Key words:** *Helicobacter pylori*; Colorectal cancer; Polyp; Adenoma; Gastrin

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: *Helicobacter pylori* (*H. pylori)*is a well-recognized gastric carcinogen; however, a causal relationship with colorectal neoplasia remains uncertain. Data from case-control and cross-sectional studies, as well as several meta-analyses, have indicated a significant, although modest, statistical association between infection with *H. pylori*/*H. pylori*-related gastritis and the development of colorectal adenomas or cancer. Potential tumorigenic actions of *H. pylori* to colorectal mucosa include induction of inflammatory responses, alteration of gut microflora and release of toxins and/or hormonal mediators.

Papastergiou V, Karatapanis S, Georgopoulos SD. *Helicobacter pylori* and colorectal neoplasia: Is there a causal link? *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of cancer-related death, accounting for > 9% of all cancer incidence[[1-3](#_ENREF_1)]. Benign neoplastic polyps, namely tubular and villous adenomas, are premalignant lesions of the colon and rectum which have the potential to progress into invasive cancer[[4](#_ENREF_4),[5](#_ENREF_5)]. Colonic carcinogenesis is believed to be a multifactorial process; however, the direct etiology of CRC remains uncertain[[2](#_ENREF_2)]. Approximately 5%-10% of CRC cases arise as a consequence of recognized hereditary conditions, although the majority are sporadic forms in subjects without family history or any apparent predisposing condition[[6](#_ENREF_6)]. In addition to familial propensity and the influence of genetic factors, environmental factors, such as Western dietary practices, smoking, and alcohol consumption, have been linked to an increased risk of CRC[[7](#_ENREF_7),[8](#_ENREF_8)]. Unsurprisingly, given the sheer numbers of bacteria that populate the gastrointestinal tract, there has been growing interest in the relationship between infectious agents and colonic carcinogenesis.

*Helicobacter pylori* (*H. pylori*) is an ubiquitous human pathogen infecting approximately 50% of the population worldwide and up to 80% in developing countries[[9](#_ENREF_9)]. After colonizing the gastric mucosa, *H. pylori* induces chronic inflammation that culminate in the development of prevalent upper digestive disorders such as chronic gastritis and peptic ulcer disease[[10](#_ENREF_10)]. Moreover, *H. pylori* is a recognized class I carcinogen which plays a causal role in the development of gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma (MALT)[[11-13](#_ENREF_11)]. Ever since *H. pylori* has been established as the single infectious agent to cause gastric cancer, studies on its oncogenicity have been extended to examine its role in the development of other gastrointestinal malignancies. There is conflicting evidence on the relevance of chronic infection by *H. pylori* as a risk factor for colorectal neoplasia. Indeed, some investigations have shown a statistical relationship[[14-20](#_ENREF_14)], disputed by others[[21-29](#_ENREF_21)].

The present article is aimed to a concise review on the possible causal relationship between *H. pylori* infection and colorectal neoplasia. Moreover, we discuss potential mechanisms by which the bacterium could exert oncogenic actions on the colonic mucosa. For these purposes, MEDLINE/PubMed was searched up to April 2015, using a combination of the following keywords: *Helicobacter pylori*, adenoma, colonic polyps, colorectal carcinoma, colorectal cancer, colon cancer and colonic neoplasms. We also reviewed the reference lists of all relevant articles retrieved in this search. Language was restricted to English and all data had to be published in a peer review journal.

***H. PYLORI* INFECTION STATUS AND COLORECTAL NEOPLASIA**

***Case-control studies***

Several case-control studies have assessed the odds of colorectal neoplasia development with respect to *H. pylori* infection (Table 1). Occurrence of CRC has been the most commonly evaluated outcome, whereas seroprevalence relying on immunoglobulin G (IgG) detection has been the most common measure of *H. pylori* infection status. The results have been dramatically inconsistent, with some studies demonstrating a positive correlation[[14-20](#_ENREF_14), [30](#_ENREF_30)], in contrast to others showing null or inverse associations[[14](#_ENREF_14),[21-29](#_ENREF_21)]. This may be due to the fact that most of the studies suffered from inherent limitations including relatively small case samples (in most studies < 250 patients) and hospital-based design which may have resulted in patient selection bias. Two population-based studies, one conducted in Japan (*n =* 478)[[17](#_ENREF_17)] and another one from Germany (*n =* 3381)[[30](#_ENREF_30)], have both confirmed a significant correlation between *H. pylori* seroprevalence and the risk of colorectal adenomas and CRC respectively.

Evaluation based on serologic testing does not discriminate between current and past infections, a distinction likely to be relevant with respect to oncogenesis, and may yield positive results for Helicobacter species other than *H. pylori*[[31](#_ENREF_31)]. However, two studies relying on 13C-urea breath test (UBT) failed to demonstrate a relevant association with the risk of CRC[[26](#_ENREF_26),[32](#_ENREF_32)]. Contrarily, a Japanese study using a combination of three non-serological detection methods (UBT, rapid urease test and histology) pointed out a positive association with both colonic adenomas and CRC[[15](#_ENREF_15)]. Apart from methodological weaknesses relative to *H. pylori* detection, a series of other limitations may have had an influence on the results. Firstly, few of the investigations excluded patients with a history of *H. pylori* eradication therapy[[15](#_ENREF_15),[19](#_ENREF_19)], thus the cancerogenic risk may have been underestimated due to the inclusion of *H. pylori*-negative CRC cases formerly exposed to the bacterium. Secondly, misestimations may have occurred due to the lack of data regarding previous colonoscopy with polyp removal. Thirdly, these studies may have been hampered by disparities in factors reflecting the carcinogenic risk, as most investigations controlled solely for age and gender or relied on a convenience sample. A recent population-based study has highlighted the importance of proper adjustment: including 1712 incident colorectal cancer cases and 1669 controls, the age- and sex-adjusted odds ratio (OR) was 1.30 [95% confidence interval (CI): 1.14-1.50][[30](#_ENREF_30)]. However, adjustment for known CRC risk factors (country of birth, educational level, smoking, average lifetime physical activity and alcohol consumption, body mass index, diabetes, history of CRC in first-degree-relative, use of non-steroidal anti-inflammatory drugs and hormone replacement therapy in females) has decreased the odds ratio to 1.26 (95%CI: 1.09-1.47), whereas a further reduction to 1.8 (95%CI: 1.02-1.45) was observed after additional adjustment for previous colorectal endoscopy. These relatively small ORs underscore the need for rigorous adjustment for confounders, as well as adequate statistical power, in studies assessing the relationship between gastric *H. pylori* infection and the risk of colorectal neoplasia.

***Cross-sectional studies***

In recent years, a number of cross-sectional hospital-based studies examined a possible association between *H. pylori* infection and colorectal neoplasia. In an Asian study including 9311 asymptomatic subjects > 40 years, detection of *H. pylori* using biopsy urease testing was an independent predictor for colorectal adenoma (OR = 1.36, 95%CI: 1.23-1.52) after controlling for several confounders including gender, age, smoking and alcohol consumption[[33](#_ENREF_33)]. The study also pointed concomitant metabolic syndrome as a factor associated with a further increased risk of colorectal adenomas (OR = 1.41, 95%CI: 1.23-1.61). In a study with 2195 (1253 cases) asymptomatic average-risk subjects from Korea, Hong *et al*[[34](#_ENREF_34)] determined a positive association between *H. pylori* seropositivity and the risk for overall (OR = 1.36, 95%CI: 1.10-1.68) and advanced (OR = 2.21, 95%CI: 1.41-3.48) adenoma after adjusting for several factors including a family history of CRC and regular use of aspirin. Similarly, a small (*n =* 273) study from Israel has pointed a positive association with both advanced colorectal neoplasia (adjusted OR = 9.57, 95%CI: 4.31-21.2) and CRC (adjusted OR = 7.98, 95%CI: 3.16-20.16)[[35](#_ENREF_35)]. In line with these previous reports, a study focusing on African-Americans (*n =* 1256), a population with a high burden of *H. pylori* infection[[36](#_ENREF_36)], found an increased risk of colorectal polyps in *H. pylori-*infected than non-infected subjects (OR = 1.95, 95%CI: 1.2-1.9)[[37](#_ENREF_37)]. However, results should be interpreted cautiously, as the authors did not perform adjustments for potential confounders. Contrarily, the association between *H. pylori* and colorectal adenomas was not relevant in a cohort of US Hispanics[[38](#_ENREF_38)], a population in which the seroprevalence of *H. pylori* infection is high whilst the risk of CRC is relatively low[[39](#_ENREF_39)]. However, due to the multifactorial nature of CRC, epidemiological associations are difficult to draw and are not appropriate for establishing a causal effect. This may in turn be reflected in the fact that the geographical and temporal trends of CRC do not overlap with those of gastric cancer in many parts of the world (*e.g*., Japan, where the incidence rates of stomach cancer decline, in parallel with increasing incidence of CRC)[[40](#_ENREF_40)].

In conclusion, although many cross-sectional studies have outlined a positive association, the possibility exists that the results have been dramatically influenced by bias including improper selection of patients, retrospective reporting of data, and disparities with respect to several factors affecting the cancerogenic risk. Last but not the least, it should be emphasized that cross-sectional studies may only establish associations and are not relevant to prove causality.

***Meta-analyses of published studies***

At least seven meta-analyses have pooled data to evaluate the relationship between *H. pylori* infection and the development of colorectal neoplasia (Table 2)[[34](#_ENREF_34),[41-46](#_ENREF_41)]. In a 2006 meta-analysis, Zumkeller *et al*[45]summarized data from 11 case-control studies (899 CRC cases, 1476 controls) and the pooled OR for CRC was 1.4 (95%CI: 1.1-1.8). However, different testing methods were combined to assess the *H. pylori* infection status. In a later analysis, Zhao *et al*[[45](#_ENREF_45)] included a total of 13 case-control studies and found comparable results (OR = 1.49, 95%CI: 1.17-1.91). Nonetheless, the authors performed a separate analysis of ten studies using IgG response as the only testing method, the results of which revealed a slightly higher OR (1.56, 95%CI: 1.14-2.14). More recent meta-analyses combined data from both case-control and cross-sectional studies to evaluate *H. pylori* in relation to colorectal adenomas. In a meta-analysis of ten studies (15.863 subjects), including their own cross-sectional study, Hong *et al*[[34](#_ENREF_34)] found that the pooled OR for colorectal adenoma related to *H. pylori* infection was 1.58 (95%CI: 1.32-1.88). In 2013, three updated meta-analyses, each one comprising more than 20 studies, confirmed a positive association between *H. pylori* infection and CRC or adenoma[[42](#_ENREF_42),[43](#_ENREF_43),[46](#_ENREF_46)]. Nonetheless, by analyzing a total of 16 sets of data, Rokkas *et al*[[42](#_ENREF_42)] pointed out a statistically significant relationship between *H. pylori* infection and colon polyps (OR = 1.5, 95%CI: 1.26-1.79).

Although meta-analyses converge to a modest positive association, results could have been influenced by inevitable heterogeneity among the included studies. Moreover, each of the analyses could incorporate the biases of the individual studies, discussed above. Notably, there is considerable overlap of underlying studies between the meta-analyses, with most of the data coming from Western countries, whilst Asian data mostly comes from Japan. Thus, concerns may arise about the generalizability of the results in other populations and/or geographical locations. Indeed, a recent meta-analysis based on East-Asian population (9 studies, 2081 cases and 5598 controls) questioned the association between *H. pylori* infection and the overall risk of colorectal neoplasia (hyperplastic polyps, adenomas and CRC), and only a heightened risk of developing colorectal adenoma was found (OR = 1.83, 95%CI: 1.35-2.51)[[41](#_ENREF_41)]. In regional sub-analysis the association between *H. pylori* infection and colorectal neoplasms was only significant in the Japanese population though, as noted by the authors, significant statistical heterogeneity limited the conclusions.

***H. PYLORI*-RELATED CHRONIC GASTRITIS AND COLORECTAL NEOPLASIA**

Sonnenberg *et al*[47] conducted the largest case-control study to date, aiming to determine the association between *H. pylori*-related gastritis and colorectal neoplasia. Using a national database of surgical pathology reports from the US, the authors analyzed 156000 patients (mean age: 58.7 years, 41% males) who underwent bidirectional endoscopy on the same day with biopsies from both procedures[[47](#_ENREF_47)]. *H. pylori* gastritis was defined as chronic active inflammation in the gastric mucosa with presence of *H. pylori* organisms demonstrated by immunohistochemistry. According to the results, patients with *H. pylori* gastritis were more likely than patients without *H. pylori* to have hyperplastic polyps (OR = 1.24, 95%CI: 1.18-1.30), adenomatous polyps (1.52, 1.46-1.57), advanced adenomas (1.80, 1.69-1.92), villous adenomas or adenomas with high-grade dysplasia (1.97, 1.82-2.14) and adenocarcinomas (2.35, 1.98-2.80). Noticeably, the risk was found to increase with advancing stage of the colorectal neoplasm and in relation with the size and number of the adenomas.

Use of histopathological data and the large sample are major strengths of the study by Sonnenberg *et al*[47]. However, results should be interpreted cautiously due to several limitations[[48](#_ENREF_48)]. These include: (1) the study only included a sample of subjects undergoing endoscopy, which may not be representative of the general population; (2) the results were not adjusted for confounders such as gender, age and previous use of antisecretory agents and/or antibiotics; and (3) case-control studies are not adequate to establish causal associations.

***H. PYLORI*-RELATED GASTRIC PREMALIGNANT LESIONS AND COLORECTAL NEOPLASIA**

To date, inconsistent data has been provided to support a causal link between progression to chronic atrophic gastritis and colorectal tumorigenesis. Two Japanese case-control studies with 339[[24](#_ENREF_24)] and 478[[17](#_ENREF_17)] subjects found no significant association between chronic atrophic gastritis diagnosed on the basis of serum pepsinogen (PG)-I and PG-I/II ratio (diagnostic criteria: PG-I ≤ 70 ng/mL and PG-I/II ≤ 3) and colorectal neoplasia. Including 20928 Finnish male smokers (age range: 50-69 years old) participating in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), there was no increased risk of CRC among those with low PG-I levels (< 25 μg/L; *n =* 1665) and among those with biopsy-proven atrophic gastritis (*n =* 1006) during a mean follow-up of 11.3 years[[49](#_ENREF_49)]. Similarly, hypergastrinemic atrophic gastritis patients aged > 40 years (*n =* 160) did not have a higher probability of developing CRC when compared to age- and gender-matched normogastrinemic controls with normal gastric histology in a study from Italy[[50](#_ENREF_50)]. In contrast to these previous observations, a recent report (*n =* 99) showed a higher risk of recurrence of endoscopically-resected colorectal neoplasia in patients with both a positive *H. pylori* serology and low PG levels[[51](#_ENREF_51)].

The only evidence to date supporting a positive association between gastric intestinal metaplasia and the risk of colonic neoplasms comes from the large case-control study by Sonnenberg *et al*[47]. The following conditions in the colon were all found more frequently in patients with (*n =* 5651) than without intestinal metaplasia: colon adenoma (OR = 1.82, 95%CI: 1.71-1.94), advanced adenoma (OR = 2.02, 95%CI: 1.82-2.24) and CRC (OR = 2.55, 95%CI: 1.93-3.37) development[[47](#_ENREF_47)]. Magnitude of this association was at least similar, if not higher, in comparison to *H. pylori* gastritis. Interestingly, advanced gastric lesions such as gastric adenoma and gastric cancer or lymphoma were even more strongly associated with CRC (OR = 2.84, 3.18 and 4.54 respectively). The authors did not analyze data with respect to atrophic gastritis due to the absence of multiple mapped gastric biopsy specimens required to diagnose this condition.

In summary, no solid conclusions can be drawn as yet on whether progression to gastric precancerous conditions (*i.e.,* chronic atrophic gastritis and gastric intestinal metaplasia) could enhance the risk of neoplastic transformation in the colon. Well-designed studies are warranted to clarify the existence of a potential link between colonic carcinogenesis and the presence, extent and/or histopathological severity of gastric conditions related to *H. pylori* infection.

**ASSOCIATIONS ACCORDING TO SITE AND HISTOLOGY OF COLONIC NEOPLASMS**

Previous studies have examined the relationship between *H. pylori* infection and the location of colorectal neoplasia, providing conflicting results. Zhang *et al*[[30](#_ENREF_30)] have postulated that the CRC risk elevation associated with *H. pylori* infection was essentially limited to the left colorectum with an OR of 1.22 (95%CI: 1.02-1.45). Contrarily, Hong *et al*[[34](#_ENREF_34)] supported the same for proximal neoplasms, whereas no location-based differences were found in other studies[[15](#_ENREF_15),[37](#_ENREF_37),[38](#_ENREF_38)]. Experimental data based on animal models have indicated that the mitogenic action of gastrin, a putative trophic factor for colorectal mucosa, is selective for the distal colon[[52-55](#_ENREF_52)]. Congruently, an association between hypergastrinemia and distal distribution of adenomas was determined in a prospective case-control study[[22](#_ENREF_22)]. On the other hand, enhanced production of bile acids secondary to colonic bacterial overgrowth, resulting in aberrant DNA methylation, has been considered to increase the risk of proximal CRC[[56](#_ENREF_56),[57](#_ENREF_57)]. Using serum PG levels as a marker, Inoue *et al*[[17](#_ENREF_17" \o "Inoue, 2011 #31)]. determined that the proximal adenoma risk increased stepwise with the presence and progression of *H. pylori*-related chronic gastritis, showing a maximal increase in association with chronic atrophic gastritis. Contrarily, this last condition appeared to imply no further risk with respect to distal adenomas. Unlike previous observations highlighting site-selective variations, the association between histologically-proven *H. pylori*-positive gastritis and the occurrence of colonic neoplasms was shown to be similar across different locations of the large bowel[[47](#_ENREF_47)].

Similarly to location issues, histology-based associations remain inconclusive. Using immunohistochemical methods Soylu *et al*[[58](#_ENREF_58)] have demonstrated that the prevalence of H. pylori was higher in villous type polyps. Oppositely, Jones *et al*[[59](#_ENREF_59)] showed significant associations between *H. pylori* prevalence and tubular, tubulovillous adenomas and CRC cases, but not with villous adenomas. According to Hong *et al*[[34](#_ENREF_34)], *H. pylori* seropositivity was more strongly associated with the presence of advanced adenomas (OR 2.21, 95%CI: 1.41-3.48 *vs* 1.36, 95%CI: 1.10-1.68 for overall colorectal adenoma), whereas Sonnenberg *et al*[[47](#_ENREF_47)]noticed a trend for the strength of the associations to increase between *H. pylori*-related gastritis and increasing histopathological severity of the colonic neoplasms: hyperplastic polyps (OR = 1.42), adenomas (OR = 1.82), villous adenoma or dysplasia (OR = 2.17) and CRC (OR = 2.55). Contrarily, in a study including 1256 African Americans (366 *H. pylori*-positive; assessed by immunochistochemistry on gastric specimens) the histology of colonic adenomas (advanced *vs* non-advanced) was not substantially related to *H. pylori* status[[37](#_ENREF_37)].

**POTENTIAL ONCOGENIC ACTIONS OF *H. PYLORI* TO COLORECTAL MUCOSA**

Several pathogenetic mechanisms have been put forward to explain the possible causal link between *H. pylori* infection and colorectal neoplasia. Persistent *H. pylori* exposure elicits hypergastrinemia, which is a putative trophic factor for the colorectal mucosa and thereby a plausible promoter of mutagenesis[[60](#_ENREF_60)]. Indeed, gastrin has been shown to be directly mitogenic on either normal or neoplastic colonic cells *in vitro*, whereas non-amidated gastrins resulted in hyperproliferation of colonic mucosa in transgenic mice[[61-65](#_ENREF_61)]. However, although both *in vitro* and *in vivo* data seem to confirm the tumorigenic properties of gastrin and its derivates, this association still remains unclear in humans. Several reports, including two prospective studies[[22](#_ENREF_22),[29](#_ENREF_29)], confirmed a statistical relationship between elevated serum/plasma gastrin levels and an increased risk of colorectal adenoma and/or CRC[[16](#_ENREF_16)]. However, this notion was disputed by other studies[[21](#_ENREF_21),[24](#_ENREF_24),[26](#_ENREF_26),[66](#_ENREF_66),[67](#_ENREF_67)]. Critically, differences in gastrin levels attributable to PPI use, variable follow-up duration and exclusive measurement of amidated forms of gastrin may have accounted for the conflicting results. Moreover, other human models of long-term hypergastrinemia, such as use of PPIs and Zollinger-Ellison syndrome, showed no effect on the development of colonic adenomas or CRC[[68](#_ENREF_68),[69](#_ENREF_69)]. Remarkably, CRC tumor cells have been shown to secrete gastrin themselves which likely act in an autocrine manner[[70-72](#_ENREF_70)]. Under this assumption, the hypergastrinemia observed in CRC patients is likely the epiphenomenon of gastrin secretion by tumor cells and, indeed, a fall in serum/plasma levels of gastrin has been observed following surgical resection of CRC[[73](#_ENREF_73),[74](#_ENREF_74)]. Taken together, these data support a role of gastrin, but not plainly a relation with *H. pylori*, in the development of colorectal neoplasia[[22](#_ENREF_22)].

Reduced gastric acid secretion secondary to *H. pylori*-related chronic atrophic gastritis might contribute to colorectal carcinogenesis by promoting changes in the colorectal microflora[[75](#_ENREF_75),[76](#_ENREF_76)]. It has been postulated that a selective growth of certain microbial species, such as *B. fragilis* and *E. faecalis*, may promote the development of CRC[[77-79](#_ENREF_77)]. In a recent report including 60 patients with CRC and 119 controls, Sobhani *et al*[[80](#_ENREF_80)] demonstrated a significant association between CRC and microbial dysbiosis, showing that the quantitative polymerase chain reaction (qPCR) values for Bacteroides/Prevotella were higher in CRC patients as compared to controls. Noticeably, the odds of CRC development in patients undergoing gastric surgery for peptic ulcer disease, another condition associated with a hyposecretory state, remain inconclusive[[81-84](#_ENREF_81)].

*H. pylori* is not an invader of the colonic epithelium, nor it is known to reside in the colonic mucosa. However, it moves through the colonic lumen, as indicated by reports of fecal shedding of viable *H. pylori*[[85](#_ENREF_85)]. Thus, local activation of colonic carcinogenesis may be hypothesized. In this regard, several authorities have reported detection of *H. pylori* organisms by immunohistochemistry in neoplastic colorectal tissues. Soylu *et al*[[58](#_ENREF_58)] reported a positive *H. pylori* staining in 11 out of 51 (21.6%) colonic polyps (31 tubular adenomas), whereas this rate was 1.7% for normal specimens, 15.3% for adenomas and 16.9% for CRC in a series by Jones *et al*[[59](#_ENREF_59)] including 176 specimens. Similarly, using cresyl violet staining and immunohistochemistry, Kapetanakis *et al*[[86](#_ENREF_86)] reported detection of *H. pylori* organisms in 64% and 84% of polyp (*n =* 25) and CRC (*n =* 50) specimens respectively. False positive results cannot be precluded by using immunohistochemistry, thus some authors employed PCR analysis for detection of *H. pylori* genomic material in colorectal tissue. Grahn *et al*[[87](#_ENREF_87)] detected *H. pylori* DNA in 27% of CRC specimens, comparably to 22% among patients undergoing colonoscopy for nonspecific gastrointestinal disturbances[[31](#_ENREF_31)]. Another study by Bulajic *et al*[[88](#_ENREF_88)] found that only 1.2% of malignant colorectal tissue samples were positive for *H. pylori*, compared with 6% of normal tissues.

Infection with virulent strain of *H. pylori* that express CagA gene may contribute to colorectal carcinogenesis by inducing enhanced inflammatory responses, including overproduction of cytokines such as IL-8, a known growth factor for human CRC[[89](#_ENREF_89)]. Moreover, infection with CagA-positive *H. pylori* is associated with higher levels of gastrin and a higher likelihood of progression to chronic atrophic gastritis[[90](#_ENREF_90),[91](#_ENREF_91)]. To date, at least four studies have determined a positive association between CagA seropositivity and colorectal neoplasia[[16](#_ENREF_16),[22](#_ENREF_22),[27](#_ENREF_27),[67](#_ENREF_67)], while other found no correlation[[23](#_ENREF_23),[45](#_ENREF_45),[92](#_ENREF_92)]. As in the case of gastric adenocarcinoma, additional bacterial factors might be able to drive colonic carcinogenesis through the induction of inflammatory responses and promotion of neo-angiogenesis[[93](#_ENREF_93)]. Interestingly, gastric cancer stem cells (CSCs) and recruited bone marrow-derived cells (BMDCs) have been shown to contribute to gastric cancer formation in a mouse model of chronic helicobacter infection[[94](#_ENREF_94)]. Noteworthy, preliminary data suggested increase expression of CD44 (a marker of human hematopoietic stem cells and CSCs) in 78% and 16% of patients with CRC and colorectal polyps respectively[[86](#_ENREF_86)]. Thus, a potential oncogenic action of *H.* *pylori* to colorectal mucosa mediated by the induction of a chronic inflammatory process, CSCs stimulation and recruitment of BMDCs, warrants further robust assessment.

**CONCLUSION**

Since more than two decades, several studies investigated the potential association between *H. pylori* infection and colorectal neoplasia. However, most investigations relied on relatively small hospital-based samples providing conflicting results. In more recent years, better designed population-based studies, as well as the large-scale histological series by Sonnenberg and Gienta and relevant meta-analyses have become available. Nevertheless, results should be interpreted cautiously as the possibility of bias cannot be excluded. Based on a critical analysis of available data, it appears that *H. pylori* infection/*H. pylori*-related gastritis is associated with an increased, although modest, risk of colorectal adenoma and/or CRC. However, it should be emphasized that current evidence supports nothing more than a statistical relationship, whilst a definitive proof of causality remains to be established. Similarly, it is not yet possible to determine prognostic associations between the risk of colonic neoplasia and the extent and/or histopathological severity of the gastric lesions related to *H. pylori* infection. A potential direct activation of colorectal carcinogenesis by the bacterium remains to be elucidated, as detection of the pathogen in malignant tissues, either by immunohistochemistry or PCR analysis, does not prove causality. On the other hand, experimental data have indicated a series of potential oncogenic interactions between *H. pylori* and colorectal mucosa, including induction and perpetuation of inflammatory responses, alteration of gut microflora and release of toxins and/or hormonal mediators which may contribute to tumor formation. In the future, large-scale studies with rigorous methodology are awaited to confirm *H. pylori* as an infectious contributor in the complex multifactorial process of colorectal tumorigenesis.

**REFERENCES**

1 **Haggar FA**, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg* 2009; **22**: 191-197 [PMID: 21037809 DOI: 10.1055/s-0029-1242458]

2 **Wilmink AB**. Overview of the epidemiology of colorectal cancer. *Dis Colon Rectum* 1997; **40**: 483-493 [PMID: 9106701]

3 **Boyle P**, Langman JS. ABC of colorectal cancer: Epidemiology. *BMJ* 2000; **321**: 805-808 [PMID: 11009523]

4 **Bosman F**, Yan P. Molecular pathology of colorectal cancer. *Pol J Pathol* 2014; **65**: 257-266 [PMID: 25693079 DOI: 24327]

5 **Conteduca V**, Sansonno D, Russi S, Dammacco F. Precancerous colorectal lesions (Review). *Int J Oncol* 2013; **43**: 973-984 [PMID: 23900573 DOI: 10.3892/ijo.2013.2041]

6 **Nagy R**, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. *Oncogene* 2004; **23**: 6445-6470 [PMID: 15322516 DOI: 10.1038/sj.onc.1207714]

7 **Le Marchand L**, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. *Cancer Res* 1997; **57**: 4787-4794 [PMID: 9354440]

8 **Lin OS**. Acquired risk factors for colorectal cancer. *Methods Mol Biol* 2009; **472**: 361-372 [PMID: 19107442 DOI: 10.1007/978-1-60327-492-0\_16]

9 **Moayyedi P**, Hunt RH. Helicobacter pylori public health implications. *Helicobacter* 2004; **9 Suppl 1**: 67-72 [PMID: 15347308 DOI: 10.1111/j.1083-4389.2004.00250.x]

10 **Kuipers EJ**. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. *Aliment Pharmacol Ther* 1997; **11 Suppl 1**: 71-88 [PMID: 9146793]

11 Infection with Helicobacter pylori. *IARC Monogr Eval Carcinog Risks Hum* 1994; **61**: 177-240 [PMID: 7715070]

12 **Guo Q**, Guo S, Zhang Y. Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication. *Int J Hematol* 2013; **97**: 735-742 [PMID: 23616223 DOI: 10.1007/s12185-013-1348-2]

13 **Shiotani A**, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. *Semin Cancer Biol* 2013; **23**: 492-501 [PMID: 23876852 DOI: 10.1016/j.semcancer.2013.07.004]

14 **Breuer-Katschinski B**, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H. Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. *Digestion* 1999; **60**: 210-215 [PMID: 10343134 DOI: 7661]

15 **Fujimori S**, Kishida T, Kobayashi T, Sekita Y, Seo T, Nagata K, Tatsuguchi A, Gudis K, Yokoi K, Tanaka N, Yamashita K, Tajiri T, Ohaki Y, Sakamoto C. Helicobacter pylori infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women. *J Gastroenterol* 2005; **40**: 887-893 [PMID: 16211345 DOI: 10.1007/s00535-005-1649-1]

16 **Hartwich A**, Konturek SJ, Pierzchalski P, Zuchowicz M, Labza H, Konturek PC, Karczewska E, Bielanski W, Marlicz K, Starzynska T, Lawniczak M, Hahn EG. Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer. *Int J Colorectal Dis* 2001; **16**: 202-210 [PMID: 11515678]

17 **Inoue I**, Mukoubayashi C, Yoshimura N, Niwa T, Deguchi H, Watanabe M, Enomoto S, Maekita T, Ueda K, Iguchi M, Yanaoka K, Tamai H, Arii K, Oka M, Fujishiro M, Takeshita T, Iwane M, Mohara O, Ichinose M. Elevated risk of colorectal adenoma with Helicobacter pylori-related chronic gastritis: a population-based case-control study. *Int J Cancer* 2011; **129**: 2704-2711 [PMID: 21225622 DOI: 10.1002/ijc.25931]

18 **Meucci G**, Tatarella M, Vecchi M, Ranzi ML, Biguzzi E, Beccari G, Clerici E, de Franchis R. High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. *J Clin Gastroenterol* 1997; **25**: 605-607 [PMID: 9451672]

19 **Mizuno S**, Morita Y, Inui T, Asakawa A, Ueno N, Ando T, Kato H, Uchida M, Yoshikawa T, Inui A. Helicobacter pylori infection is associated with colon adenomatous polyps detected by high-resolution colonoscopy. *Int J Cancer* 2005; **117**: 1058-1059 [PMID: 15986436 DOI: 10.1002/ijc.21280]

20 **Talley NJ**, Zinsmeister AR, Weaver A, DiMagno EP, Carpenter HA, Perez-Perez GI, Blaser MJ. Gastric adenocarcinoma and Helicobacter pylori infection. *J Natl Cancer Inst* 1991; **83**: 1734-1739 [PMID: 1770552]

21 **Fireman Z**, Trost L, Kopelman Y, Segal A, Sternberg A. Helicobacter pylori: seroprevalence and colorectal cancer. *Isr Med Assoc J* 2000; **2**: 6-9 [PMID: 10892362]

22 **Georgopoulos SD**, Polymeros D, Triantafyllou K, Spiliadi C, Mentis A, Karamanolis DG, Ladas SD. Hypergastrinemia is associated with increased risk of distal colon adenomas. *Digestion* 2006; **74**: 42-46 [PMID: 17068397 DOI: 96593]

23 **Limburg PJ**, Stolzenberg-Solomon RZ, Colbert LH, Perez-Perez GI, Blaser MJ, Taylor PR, Virtamo J, Albanes D. Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers. *Cancer Epidemiol Biomarkers Prev* 2002; **11**: 1095-1099 [PMID: 12376513]

24 **Machida-Montani A**, Sasazuki S, Inoue M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Hanaoka T, Tsugane S. Atrophic gastritis, Helicobacter pylori, and colorectal cancer risk: a case-control study. *Helicobacter* 2007; **12**: 328-332 [PMID: 17669106 DOI: 10.1111/j.1523-5378.2007.00513.x]

25 **Moss SF**, Neugut AI, Garbowski GC, Wang S, Treat MR, Forde KA. Helicobacter pylori seroprevalence and colorectal neoplasia: evidence against an association. *J Natl Cancer Inst* 1995; **87**: 762-763 [PMID: 7563155]

26 **Penman ID**, el-Omar E, Ardill JE, McGregor JR, Galloway DJ, O'Dwyer PJ, McColl KE. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. *Gastroenterology* 1994; **106**: 1263-1270 [PMID: 8174887 DOI: S0016508594001460]

27 **Shmuely H**, Passaro D, Figer A, Niv Y, Pitlik S, Samra Z, Koren R, Yahav J. Relationship between Helicobacter pylori CagA status and colorectal cancer. *Am J Gastroenterol* 2001; **96**: 3406-3410 [PMID: 11774957 DOI: 10.1111/j.1572-0241.2001.05342.x]

28 **Siddheshwar RK**, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of Helicobacter pylori in patients with colorectal polyps and colorectal carcinoma. *Am J Gastroenterol* 2001; **96**: 84-88 [PMID: 11197293 DOI: S0002-9270(00)02148-1]

29 **Thorburn CM**, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: a prospective study. *Gastroenterology* 1998; **115**: 275-280 [PMID: 9679032 DOI: S0016508598001176]

30 **Zhang Y**, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. *Am J Epidemiol* 2012; **175**: 441-450 [PMID: 22294430 DOI: 10.1093/aje/kwr331]

31 **Keenan JI**, Beaugie CR, Jasmann B, Potter HC, Collett JA, Frizelle FA. Helicobacter species in the human colon. *Colorectal Dis* 2010; **12**: 48-53 [PMID: 20050183]

32 **Liou JM**, Lin JW, Huang SP, Lin JT, Wu MS. Helicobacter pylori infection is not associated with increased risk of colorectal polyps in Taiwanese. *Int J Cancer* 2006; **119**: 1999-2000 [PMID: 16708392 DOI: 10.1002/ijc.22050]

33 **Lin YL**, Chiang JK, Lin SM, Tseng CE. Helicobacter pylori infection concomitant with metabolic syndrome further increase risk of colorectal adenomas. *World J Gastroenterol* 2010; **16**: 3841-3846 [PMID: 20698048]

34 **Hong SN**, Lee SM, Kim JH, Lee TY, Kim JH, Choe WH, Lee SY, Cheon YK, Sung IK, Park HS, Shim CS. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. *Dig Dis Sci* 2012; **57**: 2184-2194 [PMID: 22669208 DOI: 10.1007/s10620-012-2245-x]

35 **Shmuely H**, Melzer E, Braverman M, Domniz N, Yahav J. Helicobacter pylori infection is associated with advanced colorectal neoplasia. *Scand J Gastroenterol* 2014; **49**: 35-42 [PMID: 24164483 DOI: 10.3109/00365521.2013.848468]

36 **Everhart JE**, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. *J Infect Dis* 2000; **181**: 1359-1363 [PMID: 10762567 DOI: JID991098]

37 **Brim H**, Zahaf M, Laiyemo AO, Nouraie M, Pérez-Pérez GI, Smoot DT, Lee E, Razjouyan H, Ashktorab H. Gastric Helicobacter pylori infection associates with an increased risk of colorectal polyps in African Americans. *BMC Cancer* 2014; **14**: 296 [PMID: 24774100 DOI: 10.1186/1471-2407-14-296]

38 **Patel S**, Lipka S, Shen H, Barnowsky A, Silpe J, Mosdale J, Pan Q, Fridlyand S, Bhavsar A, Abraham A, Viswanathan P, Mustacchia P, Krishnamachari B. The association of H. pylori and colorectal adenoma: does it exist in the US Hispanic population? *J Gastrointest Oncol* 2014; **5**: 463-468 [PMID: 25436126 DOI: 10.3978/j.issn.2078-6891.2014.074]

39 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012; **62**: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]

40 **Jemal A**, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 1893-1907 [PMID: 20647400 DOI: 10.1158/1055-9965.EPI-10-0437]

41 **Guo Y**, Li HY. Association between Helicobacter pylori infection and colorectal neoplasm risk: a meta-analysis based on East Asian population. *J Cancer Res Ther* 2014; **10 Suppl**: 263-266 [PMID: 25693932 DOI: 10.4103/0973-1482.151482]

42 **Rokkas T**, Sechopoulos P, Pistiolas D, Kothonas F, Margantinis G, Koukoulis G. The relationship of Helicobacter pylori infection and colon neoplasia, on the basis of meta-analysis. *Eur J Gastroenterol Hepatol* 2013; **25**: 1286-1294 [PMID: 23820245 DOI: 10.1097/MEG.0b013e328363d3cd]

43 **Wu Q**, Yang ZP, Xu P, Gao LC, Fan DM. Association between Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. *Colorectal Dis* 2013; **15**: e352-e364 [PMID: 23672575 DOI: 10.1111/codi.12284]

44 **Zhao YS**, Wang F, Chang D, Han B, You DY. Meta-analysis of different test indicators: Helicobacter pylori infection and the risk of colorectal cancer. *Int J Colorectal Dis* 2008; **23**: 875-882 [PMID: 18506454 DOI: 10.1007/s00384-008-0479-z]

45 **Zumkeller N**, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk: a meta-analysis. *Helicobacter* 2006; **11**: 75-80 [PMID: 16579836 DOI: 10.1111/j.1523-5378.2006.00381.x]

46 **Chen YS**, Xu SX, Ding YB, Huang XE, Deng B. Helicobacter pylori Infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. *Asian Pac J Cancer Prev* 2013; **14**: 7613-7619 [PMID: 24460342]

47 **Sonnenberg A**, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. *Am J Gastroenterol* 2013; **108**: 208-215 [PMID: 23208272 DOI: 10.1038/ajg.2012.407]

48 **Plummer M**. *Helicobacter pylori* and colonic neoplasms. *Am J Gastroenterol* 2013; **108**: 216-217 [PMID: 23381070 DOI: 10.1038/ajg.2012.409]

49 **Laiyemo AO**, Kamangar F, Marcus PM, Taylor PR, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Atrophic gastritis and the risk of incident colorectal cancer. *Cancer Causes Control* 2010; **21**: 163-170 [PMID: 19838812 DOI: 10.1007/s10552-009-9446-4]

50 **Lahner E**, Sbrozzi-Vanni A, Vannella L, Corleto VD, Di Giulio E, Delle Fave G, Annibale B. No higher risk for colorectal cancer in atrophic gastritis-related hypergastrinemia. *Dig Liver Dis* 2012; **44**: 793-797 [PMID: 22595617 DOI: 10.1016/j.dld.2012.04.012]

51 **Inoue I**, Kato J, Yoshimura N, Maeda Y, Moribata K, Shingaki N, Deguchi H, Enomoto S, Maekita T, Ueda K, Iguchi M, Tamai H, Fujishiro M, Yamamichi N, Takeshita T, Ichinose M. Elevated risk of recurrent colorectal neoplasia with Helicobacter pylori-associated chronic atrophic gastritis: A follow-up study of patients with endoscopically resected colorectal neoplasia. *Mol Clin Oncol* 2013; **1**: 75-82 [PMID: 24649126 DOI: 10.3892/mco.2012.22]

52 **Konturek SJ**, Konturek PC, Hartwich A, Hahn EG. Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies. *Regul Pept* 2000; **93**: 13-19 [PMID: 11033048 DOI: S0167011500001737]

53 **Sobhani I**, Lehy T, Laurent-Puig P, Cadiot G, Ruszniewski P, Mignon M. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. *Gastroenterology* 1993; **105**: 22-30 [PMID: 8514038 DOI: S0016508593002264]

54 **Houli N**, Loh SW, Giraud AS, Baldwin GS, Shulkes A. Mitogenic effects of both amidated and glycine-extended gastrin-releasing peptide in defunctioned and azoxymethane-treated rat colon in vivo. *Regul Pept* 2006; **134**: 9-16 [PMID: 16297463 DOI: S0167-0115(05)00238-7]

55 **Malecka-Panas E**, Fligiel SE, Jaszewski R, Majumdar AP. Differential responsiveness of proximal and distal colonic mucosa to gastrin. *Peptides* 1997; **18**: 559-565 [PMID: 9210176 DOI: S0196-9781(97)00061-2]

56 **Lee S**, Hwang KS, Lee HJ, Kim JS, Kang GH. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. *Lab Invest* 2004; **84**: 884-893 [PMID: 15122305 DOI: 10.1038/labinvest.370010]

57 **Hawkins N**, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. *Gastroenterology* 2002; **122**: 1376-1387 [PMID: 11984524 DOI: S0016508502659293]

58 **Soylu A**, Ozkara S, Alis H, Dolay K, Kalayci M, Yasar N, Kumbasar AB. Immunohistochemical testing for Helicobacter Pylori existence in neoplasms of the colon. *BMC Gastroenterol* 2008; **8**: 35 [PMID: 18702825 DOI: 10.1186/1471-230X-8-35]

59 **Jones M**, Helliwell P, Pritchard C, Tharakan J, Mathew J. Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship? *World J Surg Oncol* 2007; **5**: 51 [PMID: 17498313 DOI: 1477-7819-5-51]

60 **Renga M**, Brandi G, Paganelli GM, Calabrese C, Papa S, Tosti A, Tomassetti P, Miglioli M, Biasco G. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. *Gut* 1997; **41**: 330-332 [PMID: 9378387]

61 **Sirinek KR**, Levine BA, Moyer MP. Pentagastrin stimulates in vitro growth of normal and malignant human colon epithelial cells. *Am J Surg* 1985; **149**: 35-39 [PMID: 3966639]

62 **Watson SA**, Durrant LG, Morris DL. Growth-promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro. *Br J Surg* 1988; **75**: 342-345 [PMID: 3359147]

63 **Wang TC**, Koh TJ, Varro A, Cahill RJ, Dangler CA, Fox JG, Dockray GJ. Processing and proliferative effects of human progastrin in transgenic mice. *J Clin Invest* 1996; **98**: 1918-1929 [PMID: 8878444 DOI: 10.1172/JCI118993]

64 **Koh TJ**, Goldenring JR, Ito S, Mashimo H, Kopin AS, Varro A, Dockray GJ, Wang TC. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. *Gastroenterology* 1997; **113**: 1015-1025 [PMID: 9287997 DOI: S0016508597004423]

65 **Koh TJ**, Dockray GJ, Varro A, Cahill RJ, Dangler CA, Fox JG, Wang TC. Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. *J Clin Invest* 1999; **103**: 1119-1126 [PMID: 10207163 DOI: 10.1172/JCI4910]

66 **Kikendall JW**, Glass AR, Sobin LH, Bowen PE. Serum gastrin is not higher in subjects with colonic neoplasia. *Am J Gastroenterol* 1992; **87**: 1394-1397 [PMID: 1415093]

67 **Selgrad M**, Bornschein J, Kandulski A, Hille C, Weigt J, Roessner A, Wex T, Malfertheiner P. Helicobacter pylori but not gastrin is associated with the development of colonic neoplasms. *Int J Cancer* 2014; **135**: 1127-1131 [PMID: 24496701 DOI: 10.1002/ijc.28758]

68 **Singh M**, Dhindsa G, Friedland S, Triadafilopoulos G. Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. *Aliment Pharmacol Ther* 2007; **26**: 1051-1061 [PMID: 17877512 DOI: APT3450]

69 **Orbuch M**, Venzon DJ, Lubensky IA, Weber HC, Gibril F, Jensen RT. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. *Dig Dis Sci* 1996; **41**: 604-613 [PMID: 8617144]

70 **Baldwin GS**, Zhang QX. Measurement of gastrin and transforming growth factor alpha messenger RNA levels in colonic carcinoma cell lines by quantitative polymerase chain reaction. *Cancer Res* 1992; **52**: 2261-2267 [PMID: 1559230]

71 **Finley GG**, Koski RA, Melhem MF, Pipas JM, Meisler AI. Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma. *Cancer Res* 1993; **53**: 2919-2926 [PMID: 8504433]

72 **Singh P**, Dai B, Wu H, Owlia A. Role of autocrine and endocrine gastrin-like peptides in colonic carcinogenesis. *Curr Opin Gastroenterol* 2000; **16**: 68-77 [PMID: 17024020 DOI: 00001574-200001000-00013]

73 **Bombski G**, Gasiorowska A, Orszulak-Michalak D, Neneman B, Kotynia J, Strzelczyk J, Janiak A, Malecka-Panas E. Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection. *Int J Colorectal Dis* 2003; **18**: 148-152 [PMID: 12548418 DOI: 10.1007/s00384-002-0420-9]

74 **Charnley RM**, Thomas WM, Stanley J, Morris DL. Serum gastrin concentrations in colorectal cancer patients. *Ann R Coll Surg Engl* 1992; **74**: 138-40; discussion 141 [PMID: 1567134]

75 **Kanno T**, Matsuki T, Oka M, Utsunomiya H, Inada K, Magari H, Inoue I, Maekita T, Ueda K, Enomoto S, Iguchi M, Yanaoka K, Tamai H, Akimoto S, Nomoto K, Tanaka R, Ichinose M. Gastric acid reduction leads to an alteration in lower intestinal microflora. *Biochem Biophys Res Commun* 2009; **381**: 666-670 [PMID: 19248769 DOI: 10.1016/j.bbrc.2009.02.109]

76 **Husebye E**. The pathogenesis of gastrointestinal bacterial overgrowth. *Chemotherapy* 2005; **51 Suppl 1**: 1-22 [PMID: 15855746 DOI: 81988]

77 **Wu S**, Morin PJ, Maouyo D, Sears CL. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. *Gastroenterology* 2003; **124**: 392-400 [PMID: 12557145 DOI: 10.1053/gast.2003.50047]

78 **Toprak NU**, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, Soyletir G. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. *Clin Microbiol Infect* 2006; **12**: 782-786 [PMID: 16842574 DOI: CLM1494]

79 **Wang X**, Allen TD, May RJ, Lightfoot S, Houchen CW, Huycke MM. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. *Cancer Res* 2008; **68**: 9909-9917 [PMID: 19047172 DOI: 10.1158/0008-5472.CAN-08-1551]

80 **Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van Nhieu J, Furet JP**. Microbial dysbiosis in colorectal cancer (CRC) patients. *PLoS One* 2011; **6**: e16393 [PMID: 21297998 DOI: 10.1371/journal.pone.0016393]

81 **Stemmermann GN**, Nomura AM, Chyou PH. Cancer incidence following subtotal gastrectomy. *Gastroenterology* 1991; **101**: 711-715 [PMID: 1860635 DOI: S001650859100313X]

82 **Bundred NJ**, Whitfield BC, Stanton E, Prescott RJ, Davies GC, Kingsnorth AN. Gastric surgery and the risk of subsequent colorectal cancer. *Br J Surg* 1985; **72**: 618-619 [PMID: 4027533]

83 **Toftgaard C**. Risk of colorectal cancer after surgery for benign peptic ulceration. *Br J Surg* 1987; **74**: 573-575 [PMID: 3620860]

84 **Lundegårdh G**, Adami HO, Helmick C, Zack M. The risk of large bowel cancer after partial gastrectomy for benign ulcer disease. *Ann Surg* 1990; **212**: 714-719 [PMID: 2256763]

85 **Parsonnet J**, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. *JAMA* 1999; **282**: 2240-2245 [PMID: 10605976 DOI: jci90034]

86 **Kapetanakis N**, Kountouras J, Zavos C, Polyzos SA, Kouklakis G, Venizelos I, Nikolaidou C, Vardaka E, Paikos D, Katsinelos P, Romiopoulos I. Helicobacter pylori infection and colorectal carcinoma: pathologic aspects. *J Gastrointest Oncol* 2012; **3**: 377-379 [PMID: 23205317 DOI: 10.3978/j.issn.2078-6891.2012.041]

87 **Grahn N**, Hmani-Aifa M, Fransén K, Söderkvist P, Monstein HJ. Molecular identification of Helicobacter DNA present in human colorectal adenocarcinomas by 16S rDNA PCR amplification and pyrosequencing analysis. *J Med Microbiol* 2005; **54**: 1031-1035 [PMID: 16192433 DOI: 10.1099/jmm.0.46122-0]

88 **Bulajic M**, Stimec B, Ille T, Jesenofsky R, Kecmanovic D, Pavlov M, Ceranic M, Schneider-Brachert W, Lowenfels A, Maisonneuve P, Löhr J. PCR detection of helicobacter pylori genome in colonic mucosa: normal and malignant. *Prilozi* 2007; **28**: 25-38 [PMID: 18356777]

89 **Brew R**, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. *Cytokine* 2000; **12**: 78-85 [PMID: 10623446 DOI: 10.1006/cyto.1999.0518]

90 **Konturek PC**, Konturek SJ, Bielanski W, Karczewska E, Pierzchalski P, Duda A, Starzynska T, Marlicz K, Popiela T, Hartwich A, Hahn EG. Role of gastrin in gastric cancerogenesis in Helicobacter pylori infected humans. *J Physiol Pharmacol* 1999; **50**: 857-873 [PMID: 10695565]

91 **Kuipers EJ**, Pérez-Pérez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. *J Natl Cancer Inst* 1995; **87**: 1777-1780 [PMID: 7473834]

92 **Strofilas A**, Lagoudianakis EE, Seretis C, Pappas A, Koronakis N, Keramidaris D, Koukoutsis I, Chrysikos I, Manouras I, Manouras A. Association of helicobacter pylori infection and colon cancer. *J Clin Med Res* 2012; **4**: 172-176 [PMID: 22719803 DOI: 10.4021/jocmr880w]

93 **Amedei A**, Munari F, Bella CD, Niccolai E, Benagiano M, Bencini L, Cianchi F, Farsi M, Emmi G, Zanotti G, de Bernard M, Kundu M, D'Elios MM. Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. *Intern Emerg Med* 2014; **9**: 303-309 [PMID: 23054412 DOI: 10.1007/s11739-012-0867-9]

94 **Zhao Y**, Feng F, Zhou YN. Stem cells in gastric cancer. *World J Gastroenterol* 2015; **21**: 112-123 [PMID: 25574084 DOI: 10.3748/wjg.v21.i1.112]

**P-Reviewer:** D'Elios MM, Hummel R **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Table 1 Overview of case-control studies evaluating the odds of colorectal neoplasia development with respect to *Helicobacter pylori* infection**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Cases/Controls, *n*** | **Matching variables** | **Measure of *H. pylori* status** | **Outcome** | **Adjusted OR (95%CI)** |
| Talley *et al*[[20](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_20)], 1991, USA | 80/252 | Convenience sample | IgG | Cancer | 1.17 (1.03-2.84) |
| Penman *et al*[[26](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_26)], 1994, UK | 42/34 | Age, Gender | UBT | Cancer | 1.31 (0.52-3.26) |
| Moss *et al*[[25](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_25)], 1995, USA | 41/41 | Age, Gender, Race | IgG | Cancer | 0.74 (0.3-1.79) |
| Meucci *et al*[[18](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_18)], 1997, Italy | 94/100 | Age, Gender | IgG | Adenoma or cancer | 1.92 (1.08-3.43) |
| Thorburn[[29](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_29)], 1998, USA2 | 233/233 | Age, Gender, Education, Region, Date | IgG | Cancer | 1.02 (0.69-1.51) |
| Breuer-Katschinski *et al*[[14](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_14)], 1999, Germany | 98/98 | Age, Gender | IgG | Polyp | 2.1 (1.12-3.92) |
| Fireman *et al*[[21](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_21)], 2000, Israel | 51/51 | Convenience sample | IgG | Cancer | 2.43 (1.00-5.59) |
| Hartwitch *et al*[[16](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_16)], 2001, Poland | 80/160 | Age, Gender | IgG, UBT | Cancer | 3.78 (1.89-7.53) |
| Shmuely *et al*[[27](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_27)], 2001, Israel | 67/92 | Convenience sample | IgG, CagA | Cancer | 1.35 (0.67-2.74) |
| Siddheshwar *et al*[[28](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_28)], 2001, UK | 189/179 | Age, Gender, Social class | IgG | Cancer  Polyp | 1.1 (0.7-1.8)  1.3 (0.7-2.5) |
| Limburg *et al*[[23](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_23)], 2002, Finland2 | 118/236 | Age, gender1, study center, date of serum collection | CagA, whole cell assay | Cancer | 0.91 (0.53-1.55) |
| Fujimori *et al*[[15](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_15)], 2005, Japan | 481/188 | Age | UBT, urease test, histological diagnosis | Adenoma  Cancer | 1.60 (1.18-2.02)  1.80 (1.28-2.32) |
|  |  |  |  |  |  |
| Inoue *et al*[[17](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_17)], 2011, Japan3 | 239/239 | Age | IgG | Adenoma | 2.52 (1.57-4.05) |
| Zhang *et al*[[30](file:///C:\Users\baishideng-2014\Desktop\revised-jyu\3-25\18193\18193_review%20~.docx#_ENREF_30)], 2012, Germany3 | 1712/1669 | Age, Gender, colorectal risk factors, former colorectal endoscopy | IgG, CagA | Cancer | 1.22 (1.02-1.45) |

1Only male smokers were included in the study; 2Nested case-control study; 3Population-based case-control studies. Data refer to studies reporting ORs or information from which such measure could be inferred. IgG: Immunoglobulin G; UBT: Urea breath test; CagA: Cytotoxin-associated gene A.

**Table 2 Published meta-analyses evaluating the relationship between *Helicobacter pylori* infection and the development of colorectal neoplasia.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | | | **Included studies, *n*** | **Outcome** | **Summary OR (95%CI)** | **Conclusion** |
| Zumkeller *et al*[[45](#_ENREF_45)], 2006, Germany | | | 111 | Cancer | 1.4 (1.1-1.8) | Possible small increase in the risk of CRC |
| Zhao *et al*[[44](#_ENREF_44)], 2008, China | | 131 (9 using IgG to detect infection status) | Cancer | 1.49 (1.17-1.91)  1.56 (1.14-2.14) evaluating IgG as the only test indicator) | Possible increase in risk of CRC |
| Hong *et al*[[34](#_ENREF_34)], 2012, South Korea | 10 | Adenoma | 1.58 (1.32-1.88) | Modest increase in the risk of colorectal adenoma |
| Wu *et al*[[43](#_ENREF_43)], 2013, China | 27 | Adenoma  Cancer | 1.66 (1.39-1.97)  1.39 (1.18-1.64) | Positive association between HP and colorectal neoplasia |
| Rokkas *et al*[[42](#_ENREF_42)], 2013, Greece | 28 | Polyps  Cancer | 1.5 (1.26-1.79)  1.3 (1.07-1.59) | Modest statistically significant relationship of HP with both cancer and polyps |
| Chen *et al*[[46](#_ENREF_46)], 2013, China | 22 | Cancer | 1.49 (1.30-1.72) | HP increases the risk of CRC |
| Guo *et al*[[41](#_ENREF_41)], 2014, China | 92 | Hyperplastic polyp  Adenoma  Cancer | 0.72 (0.44-1.180  1.83 (1.35-2.51)  1.08 (0.89-1.68) | No statistical association between HP and colorectal neoplasm was found, but HP may increase the risk of adenoma |

1Only case-control studies were included; 2Included only data based on East-Asian population. HP: *Helicobacter pylori*; IgG: Immunoglobulin G; CRC: Colorectal cancer.